You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯邦制藥(03933.HK):門冬胰島素50注射液臨牀試驗獲批
格隆匯 05-31 18:14

格隆匯5月31日丨聯邦制藥(03933.HK)發佈公吿,2021年5月25日,公司全資附屬公司珠海聯邦制藥股份有限公司接獲國家藥品監督管理局關於公司申報的門冬胰島素50注射液的臨牀試驗批准通知書,受理號為CXSL1900081。

根據披露,門冬胰島素50注射液為預混胰島素類似物,由50%可溶性門冬胰島素和50%精蛋白門冬胰島素構成。與可溶性人胰島素相比,門冬胰島素50注射液起效迅速,同時兼顧基礎血糖控制。另外,該藥在改善血糖控制、提高藥物依從性方面具有優勢。該公司將持續致力於新產品的研發,並重點提升在生物醫藥行業的競爭力及創造力,預期將為該公司及其股東創造更大收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account